Freestone Grove Partners LP Invests $14.72 Million in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Freestone Grove Partners initiated a $14.72 million position in Supernus Pharmaceuticals, buying 316,398 shares, or approximately 0.54% of the company. Other major institutions, including BlackRock, State Street and Geode Capital, also increased or initiated holdings.
• Supernus reported quarterly revenue of $219.06 million, up 32.4% year over year and above estimates, but posted a loss of $1.01 per share versus expectations for $0.42 in earnings. The stock opened at $44.19, near its 52-week low of $42.45.
• Analyst sentiment remains moderately positive, with a consensus rating of “Moderate Buy” and an average price target of $62.83, despite ratings ranging from sell to strong buy.

Freestone Grove Partners LP bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 316,398 shares of the specialty pharmaceutical company's stock, valued at approximately $14,716,000. Freestone Grove Partners LP owned 0.54% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SUPN. BlackRock Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $434,871,000. State Street Corp grew its position in shares of Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company's stock worth $110,296,000 after buying an additional 31,668 shares during the period. Geode Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company's stock worth $73,215,000 after acquiring an additional 62,875 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in Supernus Pharmaceuticals by 12.7% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company's stock valued at $72,007,000 after acquiring an additional 162,905 shares during the period. Finally, Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 4.5% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company's stock worth $69,904,000 after acquiring an additional 61,120 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $44.19 on Friday. The firm's 50 day moving average price is $46.83 and its 200-day moving average price is $48.69. Supernus Pharmaceuticals, Inc. has a 52-week low of $42.45 and a 52-week high of $59.68. The company has a market cap of $2.57 billion, a PE ratio of -23.02, a P/E/G ratio of 0.83 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same period last year, the business earned $0.40 EPS. Supernus Pharmaceuticals's revenue was up 32.4% on a year-over-year basis. On average, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SUPN has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald raised their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 6th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source